Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:18 PM
Ignite Modification Date:
2026-03-26 @ 3:18 PM
NCT ID:
NCT07395258
Eligibility Criteria:
Inclusion criteria:
1. Measurable disease as defined per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
2. Patient has 1 or more accessible lesions (2 or more preferred)
3. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
4. Life expectancy of at least ≥3 months after the start of the treatment according to the investigator's judgement Further inclusion criteria apply.
Exclusion criteria:
1. Patients with known primary brain tumors, leptomeningeal disease or untreated brain metastases. Subjects with previously treated brain metastases may participate provided the brain metastases are stable
2. Previous treatment with vesicular stomatitis virus (VSV)-based agents
3. Concomitant medication or condition considered a high risk for complications from injection
4. History of common terminology criteria for adverse events (CTCAE) v5 grade 3 or higher severe hypersensitivity reactions to previous anti-programmed cell death 1 (anti-PD-1)/anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) (Arm B only) Further exclusion criteria apply.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07395258
Study Brief:
Protocol Section:
NCT07395258